ACTRN12614000240640已完成4 期
A Prospective Study to Evaluate the Immunogenicity and Efficacy of Inactivated Trivalent Influenza Vaccine in Children (> or = 6 months to < or =18 years of age) who have Undergone Allogeneic or Autologous Haematopoietic Stem Cell Transplant compared to Aged Matched Controls
Princess Margaret Hospital for children0 个研究点目标入组 150 人开始时间: 2014年3月6日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Prevention
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 6 Months 至 18 Years（—）
- 性别
- All
入选标准
- •1.Age greater than or equal to 6 months to less than or equal to 18 years of age at time of vaccination and have undergone HSCT
- •2.HSCT recipients who are more than 6 months upto 2 years post transplant
排除标准
- •1.Known contraindication to influenza vaccine as defined in the National Health and Medical Research Council (NHMRC) Immunisation Handbook (10th ed.)
- •2.Receipt of an inappropriate dose of influenza vaccine for age of child during the current year
研究者
相似试验
进行中（未招募）
1 期
A prospective study to evaluate the immune response of UK infants receiving the 13-valent pneumococcal conjugate vaccine as part of their routine primary immunisation schedule at 2 and 4 months (code: P13UK) - P13UKPrevenar13 was introduced into the national childhood immunisation programme to prevent serious bacterial infections caused by the germ Streptococcus pneumonia, including meningitis, septicaemia and pneumonia.EUCTR2010-023865-22-GBHealth Protection Agency
已完成
4 期
Responses to booster vaccinations in UK toddlersISRCTN84763401Health Protection Agency (UK)200
已完成
3 期
A Clinical trial of Omicron-Based CovIran Barkat vaccine as a third injection dose in vaccinated population over 18 years of ageIRCT20171122037571N4SHIFAPHARMED Industrial Group Co210
已完成
3 期
Human Papilloma Virus (HPV) Vaccination in Special Risk GroupsSpecial Risk Groups1. Paediatric Rheumatalogical Disease2. Inflammatory Bowel Disease3. Acute Lymphoblastic Leukaemia4. Solid Organ Transplant Recipients (kidney and liver)5. Chronic Renal Disease6. Bone Marrow TranssplantThe response to the HPV vaccine will be studied within these 6 special risk groups.Special Risk Groups1. Paediatric Rheumatalogical Disease2. Inflammatory Bowel Disease3. Acute Lymphoblastic Leukaemia4. Solid Organ Transplant Recipients (kidney and liver)5. Chronic Renal Disease6. Bone Marrow TranssplantThe response to the HPV vaccine will be studied within these 6 special risk groups.Inflammatory and Immune System - Other inflammatory or immune system disordersACTRN12609000571279ational Health and Medical Research Council & Clinical Centre of Research Excellence(NHMRC CCRE) in Childhood and Adolescent Immunisation100
已完成
不适用
Prospective study on evaluation of immune response after SARS-CoV-2 vaccinatioHealthy SubjectJPRN-UMIN000045492Shionogi & Co., Ltd.143